

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 12/12/1972
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Acid-Fast Bacillus (AFB) Identification with Reflex to Susceptibility

ARUP test code 0060997

Collected: 00/00/0000 00:00 MT
Started: 00/00/0000 00:00 MT

Source: **Respiratory**

Body Site: **Sputum**

Free Text Sources: **Resp**

Final Report

Mycobacterium avium-intracellulare complex
Identification by MALDI-TOF
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Susceptibility Results

Organism: Mycobacterium avium-intracellulare complex

Amikacin	Interpretation: INTERMEDIATE MIC (ug/mL): 32
Clarithromycin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 1
Linezolid	Interpretation: SUSCEPTIBLE MIC (ug/mL): 8
Moxifloxacin	Interpretation: SUSCEPTIBLE MIC (ug/mL): 1

Interpretive Information Interpretation: **SEE NOTE**

For Mycobacterium avium-intracellulare complex, CLSI recommends testing and reporting clarithromycin, moxifloxacin, amikacin and linezolid. The reported amikacin interpretation is for IV; if using amikacin (liposomal, inhaled), the MIC interpretive breakpoints are ≤64 ug/mL Susceptible, >=128 ug/mL Resistant. The in vivo effectiveness of Moxifloxacin and Linezolid for MAC disease is unproven. Ethambutol, rifampin and rifabutin MIC results are not reported because MIC values are not predictive of clinical responses and may be misleading.

Susceptibility performed by a non-standardized methodology. Interpret results in conjunction with clinical presentation. Test developed and characteristics determined by ARUP Laboratories. See compliance Statement B: aruplab.com/CS.

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Acid-Fast Bacillus (AFB) Identification with Reflex to Susceptibility	22-213-400568	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

S=Susceptible, I=Intermediate, R=Resistant, NonS=Nonsusceptible, IND=Indeterminate, SDD=Susceptibility is dose dependent, None=Interpretive guidelines are not available

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-213-400568
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 8/31/2022 11:18:19 AM
4848